THTX

Theratechnologies Inc. [THTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

THTX Stock Summary

Top THTX Correlated Resources

THTX


Top 10 Correlated ETFs

THTX


Top 10 Correlated Stocks

THTX


In the News

09:11 10 Dec 2023 THTX

Why Is Theratechnologies (THTX) Stock Down 22% Today?

Theratechnologies (NASDAQ: THTX ) stock is dropping on Thursday after the biopharmaceutical company announced a proposed public share offering. Theratechnologies is selling 12.5 million shares of THTX stock at a price of $1 per share.

07:00 10 Dec 2023 THTX

Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023

MONTREAL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Paul Lévesque, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Fitzgerald Global Healthcare Conference 2023 being held September 26-28 in New York City.

04:15 10 Dec 2023 THTX

Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update

MONTREAL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2023, on Tuesday, September 26 at 8:30 a.m. EDT.

01:57 10 Dec 2023 THTX

Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference

MONTREAL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Lévesque, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, to be held virtually and in person on September 11-13, 2023, in New York City at the Lotte New York Palace Hotel.

07:30 10 Dec 2023 THTX

Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update

MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter ended May 31, 2023, on Wednesday, July 12 at 8:30 a.m. EDT.

05:31 10 Dec 2023 THTX

Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug conjugate (PDC) candidate, sudocetaxel zendusortide (formerly TH1902), in patients with advanced solid tumors. In a June 3 poster session at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, researchers will present early results from Part 1 (dose escalation) and Part 2 (dose expansion) of the multicenter, open-label trial of sudocetaxel zendusortide, in which 36% of heavily pretreated participants experienced a clinical benefit, including two patients with partial responses (PR) and seven achieving prolonged stable disease (SD).

07:30 10 Dec 2023 THTX

Theratechnologies to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Montreal, Quebec--(Newsfile Corp. - April 18, 2023) - Theratechnologies (NASDAQ: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre. Dates: Tuesday April 25, 2023-Wednesday April 26, 2023 Time: 8:30 AM-4:30 PM ET Location:  Metro Toronto Convention Centre, North Building 255 Front St W Toronto, Ontario M5V 2W6   Paul Levesque will be speaking at 11:30 ET on April 25th.

02:33 10 Dec 2023 THTX

Theratechnologies stock price continues higher on company guidance

Theratechnologies (TSX:TH) Inc shares continued to advance Friday, up 12% to $1.29 following a 10% gain on Thursday, after the biopharmaceutical company announced that it expects its fiscal year 2023 revenue to be in the range of between $90 million and $95 million, representing commercial portfolio growth of between 13% and 19% over the past year. Theratechnologies (TSX:TH) also reported that its first quarter 2023 consolidated revenue rose 7.3% year-over-year to US$19,908,000, as sales of EGRIFTA SV reached US$12,711,000 and Trogarzo sales increased 5% to US$7,197,000 during the period.

11:51 10 Dec 2023 THTX

Theratechnologies Inc. (THTX) Q1 2023 Earnings Call Transcript

Theratechnologies Inc. (NASDAQ:THTX ) Q1 2023 Earnings Conference Call April 12, 2023 8:30 AM ET Company Participants Elif McDonald - Head of Investor Relations Paul Levesque - President and Chief Executive Officer John Leasure - Global Commercial Officer Philippe Dubuc - Chief Financial Officer Christian Marsolais - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Justin Walsh - JonesTrading Edward Nash - Canaccord Genuity Endri Leno - National Bank Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies First Quarter Fiscal Year 2023 Earnings Call.

10:47 10 Dec 2023 THTX

Theratechnologies shares up as first quarter revenues rise

Theratechnologies (TSX:TH) has reported first-quarter financial results with consolidated revenue growing by 7% to US$19.9mln. The Montreal-headquartered biopharmaceutical firm told investors that the performance was supported by a 9% growth in revenue from the EGRIFTA SV product along with 5% growth for Trogarzo which are both used by patients with HIV.

THTX Financial details

Company Rating
Neutral
Market Cap
38.72M
Income
-29.13M
Revenue
79.73M
Book val./share
-1.72
Cash/share
0.95
Dividend
-
Dividend %
-
Employees
144
Optionable
No
Shortable
Yes
Earnings
26 Feb 2024
P/E
-1.33
Forward P/E
-2.08
PEG
1.08
P/S
0.49
P/B
-0.93
P/C
1.68
P/FCF
-3.81
Quick Ratio
0.33
Current Ratio
0.42
Debt / Equity
-1.4
LT Debt / Equity
-0.02
-
-
EPS (TTM)
-1.2
EPS next Y
-0.77
EPS next Q
-0.09
EPS this Y
44.53%
EPS next Y
-35.88%
EPS next 5Y
-35.88%
EPS last 5Y
51.27%
Revenue last 5Y
12.1%
Revenue Q/Q
18.84%
EPS Q/Q
-92.49%
-
-
-
-
SMA20
42.98%
SMA50
-22.38%
SMA100
-52.34%
Inst Own
0.2%
Inst Trans
0.01%
ROA
-51%
ROE
84%
ROC
0.46%
Gross Margin
74%
Oper. Margin
-24%
Profit Margin
-37%
Payout
-
Shs Outstand
24.2M
Shs Float
14.52M
-
-
-
-
Target Price
-
52W Range
0.88-4.72
52W High
-
52W Low
-
RSI
54.41
Rel Volume
0.16
Avg Volume
206.97K
Volume
33.64K
Perf Week
-2.43%
Perf Month
73.74%
Perf Quarter
-56.99%
Perf Half Y
-59.59%
-
-
-
-
Beta
1.606
-
-
Volatility
0.03%, 0.25%
Prev Close
0.95%
Price
1.6001
Change
-4.76%

THTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-11-30

Metric History 2018-11-302019-11-302020-11-302021-11-30 2022-11-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.383.293.433.023.36
Net income per share
-0.25-0.65-1.18-1.37-1.98
Operating cash flow per share
0-0.18-0.7-0.63-0.62
Free cash flow per share
0-0.36-0.71-0.63-0.66
Cash per share
2.562.111.081.751.39
Book value per share
1.151.290.170.77-0.95
Tangible book value per share
0.15-0.77-1.49-0.26-1.58
Share holders equity per share
1.151.290.170.77-0.95
Interest debt per share
2.493.973.162.73.07
Market cap
467.81M243.09M177.08M304.76M202.89M
Enterprise value
428.81M265.17M219.73M341.1M245.74M
P/E ratio
-99.53-19.45-7.81-9.61-4.3
Price to sales ratio
10.353.852.684.362.53
POCF ratio
5.08K-71.69-13.06-21.05-13.81
PFCF ratio
6.98K-34.66-13.03-20.81-12.94
P/B Ratio
21.49.7954.9317.16-8.99
PTB ratio
21.49.7954.9317.16-8.99
EV to sales
9.484.193.334.893.07
Enterprise value over EBITDA
640.976.63K-23.94-20.9-9.05
EV to operating cash flow
4.66K-78.2-16.21-23.56-16.73
EV to free cash flow
6.4K-37.81-16.17-23.29-15.68
Earnings yield
-0.01-0.05-0.13-0.1-0.23
Free cash flow yield
0-0.03-0.08-0.05-0.08
Debt to equity
2.252.8717.183.2-2.96
Debt to assets
0.440.610.550.480.72
Net debt to EBITDA
-58.29552-4.65-2.23-1.58
Current ratio
2.742.051.552.040.64
Interest coverage
1.86-1.71-3.35-4.46-6.14
Income quality
-0.020.270.60.460.31
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.130.130.190.210.22
Research and developement to revenue
0.180.170.270.40.46
Intangibles to total assets
0.290.340.320.20.16
Capex to operating cash flow
-0.271.0700.010.07
Capex to revenue
0-0.0600-0.01
Capex to depreciation
-0.01-0.480-0.02-0.08
Stock based compensation to revenue
0.020.020.020.030.05
Graham number
2.534.342.114.886.5
ROIC
-0.06-0.12-0.29-0.33-0.87
Return on tangible assets
-0.06-0.16-0.33-0.33-0.6
Graham Net
-1.15-1.77-2.79-1.66-2.67
Working capital
46.74M39.04M22.89M46.83M-40.91M
Tangible asset value
2.8M-14.85M-28.63M-6.07M-37.58M
Net current asset value
-2.5M-16.54M-32.11M-9.54M-42.46M
Invested capital
2.252.8717.183.2-2.96
Average receivables
05.06M11.65M12.06M11.64M
Average payables
10.49M14.34M15.31M16.52M14.21M
Average inventory
9.16M16.01M23.04M27.14M24.41M
Days sales outstanding
058.4172.8657.1356.28
Days payables outstanding
302.3183.45237.57243.64178.98
Days of inventory on hand
215.02292.95341.16457.29273.45
Receivables turnover
06.255.016.396.49
Payables turnover
1.211.991.541.52.04
Inventory turnover
1.71.251.070.81.33
ROE
-0.21-0.5-7.03-1.792.09
Capex per share
0-0.190-0.01-0.04

Quarterly Fundamentals Overview

Last date of statement is 2023-08-31 for Q3

Metric History 2022-08-312022-11-302023-02-282023-05-31 2023-08-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.880.90.820.730.86
Net income per share
-0.32-0.33-0.43-0.41-0.03
Operating cash flow per share
-0.05-0.34-0.14-0.150.22
Free cash flow per share
-0.08-0.35-0.15-0.150.22
Cash per share
1.531.381.21.050.95
Book value per share
-0.76-0.94-1.34-1.72-1.72
Tangible book value per share
-0.76-1.57-1.34-1.72-1.72
Share holders equity per share
-0.76-0.94-1.34-1.72-1.72
Interest debt per share
2.862.882.822.862.52
Market cap
205.48M203.71M91.97M91.97M23.23M
Enterprise value
248.5M246.57M137.93M141.68M66.51M
P/E ratio
-6.8-6.42-2.2-2.3-7.79
Price to sales ratio
9.879.514.625.241.11
POCF ratio
-171.81-24.71-27.54-25.824.36
PFCF ratio
-113.46-24.65-25.83-25.244.37
P/B Ratio
-11.38-9.03-2.85-2.21-0.56
PTB ratio
-11.38-9.03-2.85-2.21-0.56
EV to sales
11.9411.516.938.073.19
Enterprise value over EBITDA
-53.93-53.53-32.37-20.8161.35
EV to operating cash flow
-207.78-29.91-41.31-39.7812.48
EV to free cash flow
-137.22-29.83-38.73-38.8912.52
Earnings yield
-0.04-0.04-0.11-0.11-0.03
Free cash flow yield
-0.01-0.04-0.04-0.040.23
Debt to equity
-3.68-2.96-2.04-1.61-1.4
Debt to assets
0.690.720.830.971.03
Net debt to EBITDA
-9.34-9.3-10.79-7.339.92
Current ratio
1.050.640.840.720.42
Interest coverage
-3.57-2.53-2.33-3.20.02
Income quality
0.161.040.320.36-7.14
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.20.180.220.210.18
Research and developement to revenue
0.40.440.470.590.26
Intangibles to total assets
0.130.160.180.20.23
Capex to operating cash flow
0.5100.070.020
Capex to revenue
-0.030-0.0100
Capex to depreciation
-0.72-0.02-0.24-0.09-0.02
Stock based compensation to revenue
0.040.040.030.040.02
Graham number
2.332.653.641.09
ROIC
-0.11-0.13-0.16-0.310
Return on tangible assets
-0.09-0.1-0.16-0.18-0.02
Graham Net
-2.41-2.66-2.77-2.9-2.7
Working capital
3.38M-40.91M-12.01M-20.19M-57.09M
Tangible asset value
-30.91M-37.58M-46.58M-55.06M-54.56M
Net current asset value
-36.04M-42.46M-50.62M-59.14M-57.83M
Invested capital
-3.68-2.96-2.04-1.61-1.4
Average receivables
5.77M11.94M11.36M11.99M11.36M
Average payables
42.32M26.98M23.48M33.84M32.03M
Average inventory
24.06M21.41M17.4M12.14M7.94M
Days sales outstanding
49.8651.8646.9469.7639.34
Days payables outstanding
698.57196.27653.63616.1551.87
Days of inventory on hand
393.55299.87289.77167.97121.82
Receivables turnover
1.81.741.921.292.29
Payables turnover
0.130.460.140.150.16
Inventory turnover
0.230.30.310.540.74
ROE
0.420.350.320.240.02
Capex per share
-0.030-0.0100

THTX Frequently Asked Questions

What is Theratechnologies Inc. stock symbol ?

Theratechnologies Inc. is a CA stock , located in Montreal of Qc and trading under the symbol THTX

What is Theratechnologies Inc. stock quote today ?

Theratechnologies Inc. stock price is $1.6001 today.

Is Theratechnologies Inc. stock public?

Yes, Theratechnologies Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap